当前位置:
X-MOL 学术
›
J. Med. Chem.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity.
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2001 Aug 16 Thomas, J B, Atkinson, R N, Rothman, R B, Fix, S E, Mascarella, S W, Vinson, N A, Xu, H, Dersch, C M, Lu, Y, Cantrell, B E, Zimmerman, D M, Carroll, F I
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2001 Aug 16 Thomas, J B, Atkinson, R N, Rothman, R B, Fix, S E, Mascarella, S W, Vinson, N A, Xu, H, Dersch, C M, Lu, Y, Cantrell, B E, Zimmerman, D M, Carroll, F I
A structurally novel opioid kappa receptor selective ligand has been identified. This compound, (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl ]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic, 10) demonstrated high affinity for the kappa receptor in the binding assay (kappa K(i) = 0.3 nM) and highly potent and selective kappa antagonism in the [(35)S]GTP-gamma-S assay using cloned opioid receptors (kappa K(i) = 0.006 nM, mu/kappa ratio = 570, delta/kappa ratio > 16600).
中文翻译:
鉴定第一个反式-(3R,4R)-二甲基-4-(3-羟苯基)哌啶衍生物具有高度有效和选择性的阿片类κ受体拮抗剂活性。
已经鉴定出结构上新颖的阿片样κ受体选择性配体。该化合物,(3R)-7-羟基-N-((1S)-1-[[((3R,4R)-4-(3-羟基苯基)-3,4-二甲基-1-哌啶基]甲基] -2 -甲基丙基)-1,2,3,4-四氢-3-异喹啉甲酰胺(JDTic,10)在结合测定中显示出对kappa受体的高度亲和力(kappa K(i)= 0.3 nM)以及高度有效和选择性的kappa拮抗作用在[(35)S]GTP-γ-S分析中使用克隆的阿片受体(kappa K(i)= 0.006 nM,mu / kappa比率= 570,delta / kappa比率> 16600)。
更新日期:2017-01-31
中文翻译:
鉴定第一个反式-(3R,4R)-二甲基-4-(3-羟苯基)哌啶衍生物具有高度有效和选择性的阿片类κ受体拮抗剂活性。
已经鉴定出结构上新颖的阿片样κ受体选择性配体。该化合物,(3R)-7-羟基-N-((1S)-1-[[((3R,4R)-4-(3-羟基苯基)-3,4-二甲基-1-哌啶基]甲基] -2 -甲基丙基)-1,2,3,4-四氢-3-异喹啉甲酰胺(JDTic,10)在结合测定中显示出对kappa受体的高度亲和力(kappa K(i)= 0.3 nM)以及高度有效和选择性的kappa拮抗作用在[(35)S]GTP-γ-S分析中使用克隆的阿片受体(kappa K(i)= 0.006 nM,mu / kappa比率= 570,delta / kappa比率> 16600)。